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Rationale and Aim  
Bowel symptoms are common, and community pharmacies are an ideal setting for health advice 
about these symptoms. The aim of this study was to develop and validate a questionnaire for use 
with adults presenting to community pharmacies with lower bowel symptoms.  The purpose of the 
questionnaire was to stratify people into those requiring medical follow-up for symptoms, and those 
with self-limiting symptoms. 
Method 
A self-administered questionnaire, named the Jodi-Lee test (JLT), was developed in three stages: 
review of the literature, questionnaire design, and statistical validation against a validated screening 
tool, the Patient Consultation Questionnaire (PCQ) to assess the sensitivity and specificity of JLT. The 
questionnaire was developed to be simple, easy for all pharmacy staff to use, and require no score 
calculation. Its application was designed to facilitate referral from pharmacy assistants to 
pharmacists and from pharmacists to medical practitioners. 
Results 
The questionnaire comprises eight questions. It has a Flesh-Kincaid reading score of 79.5. By 
considering different score thresholds on the PCQ, a receiver operator characteristic (ROC) curve 
was calculated to assess effectiveness of the JLT. From a sample of 118 subjects, the area under the 
ROC curve was 0.94. At a threshold score of 30 on the PCQ, the sensitivity was 100%. The specificity 
was 65%. 
Conclusion 
The JLT has high sensitivity for identifying patients with symptoms of serious bowel disease. It is also 






Community pharmacies provide health information and services to their clients,1 and are ideal 
settings for health screening services.2, 3 There are over 200 million occasions each year where 
pharmacists in Australia may be accessed for health advice and service.4 Around half of all visits to 
Australian community pharmacies are to buy either prescribed or over-the-counter (OTC) 
medication, and one-third of the visits are to ask advice about a health issue.5  
Lower bowel symptoms are a common experience.6, 7 A number of lower bowel diseases share 
clinical presentations, and certain symptom profiles are associated with serious underlying 
conditions such as cancer, inflammatory bowel disease or degenerative bowel conditions.8 Data 
suggest that one in 15 people identify the pharmacist as a source of advice about lower bowel 
symptoms.9  
Despite this, in a survey of pharmacists in Western Australia, it was demonstrated that bowel 
symptoms indicative of serious disease were not recognised in a significant proportion of cases, and, 
more recently, that other chronic conditions were not recognised, even when clients requested 
over-the-counter treatments.10  Data suggest that pharmacists and general practitioners (GPs) have 
not consistently recognised presentations of significant colorectal pathology.10-12 Some research 
supports the use of self-administered questionnaires to help identify cases that need further 
investigation for colorectal pathology.13, 14 
The CRISP (Colonoscopy Research into Symptom Prediction) Study 14, 15 developed and validated a 
bowel symptom questionnaire to be deployed during medical consultations. Similarly, the Patient 
Consultation Questionnaire (PCQ) assists doctors to prioritise colorectal referrals, and has high 
sensitivity for serious colorectal pathologies.8, 16 The PCQ identifies people at highest risk, based on a 
numeric score for symptoms.8, 13, 16, 17 It was validated in the context of patients referred to 
specialists by GPs. A feasibility study of the PCQ in 21 Western Australian community pharmacies 
identified that the majority of patients presenting to pharmacies had low PCQ scores, indicating a 
low risk of serious pathology.11  This is consistent with the profile of a population who seek over-the-
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counter symptomatic treatment in a developed country.18 However, there were three main 
problems with implementing PCQ in pharmacies: 
 The PCQ has 14 questions and several sub-questions, and takes 10 minutes to complete.  The 
consensus among pharmacy staff was that a shorter and simpler questionnaire was required. 
 Reference to a computerised scoring schedule was required to rank the health of the patient 
from the completed PCQ, thus limiting the application of the tool in practice.  
 In practice, patients may present with multiple conditions, which although identified as benign 
and self-limiting on the PCQ, may benefit from the advice of a GP (e.g. severe haemorrhoids, 
persistent diarrhoea and recurrent constipation).19, 20 
A simpler screening tool is needed with high sensitivity for bowel disease, to triage of clients 
presenting with bowel symptoms at pharmacies.  In WA, the law requires that customers must 
interact with a pharmacy staff member before they can purchase over-the-counter products for 
treatment of diarrhoea and rectal bleeding.21 This affords an opportunity to test the value of a 
simple triage tool to help pharmacists and pharmacy staff to identify symptomatic patients who 
should be referred to a medical practitioner. 
Aim 
The aim of this study was to develop and validate a questionnaire for use with people presenting to 
a community pharmacy with lower bowel symptoms. 
Method 
A self-administered questionnaire, named the ‘Jodi Lee Test’ (JLT) to acknowledge the Foundation 
sponsoring this research (www.jodileefoundation.org.au), was developed in three stages – review of 
relevant literature, questionnaire construction, and statistical validation against an existing validated 
screening tool, the Patient Consultation Questionnaire or PCQ.  
Given the limitations of the PCQ in pharmacy settings (noted in the introduction), the JLT was 
designed with two features in mind. Firstly, the instrument had to be usable by all pharmacy staff 
who interact with clients: e.g. pharmacy assistants to determine when referral to a pharmacist is 
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warranted and pharmacists to determine when referral to a GP is warranted. Secondly, the 
instrument was intended to act as a guide to clinical decision making by the pharmacist. For these 
reasons, a ‘check-list’ approach was determined to be more appropriate in a pharmacy setting 
rather than to compute a risk score. 
Literature Review 
A systematic literature review was conducted to identify the risk factors for bowel disease. Reports 
of published measurement instruments were also reviewed to determine if any could be modified 
for our purpose. A search strategy was developed to source peer-reviewed English-language papers 
using CINAHL, PubMed and Scopus databases, with combinations of the following search terms: 
‘bowel symptoms’ OR ‘bowel disease’; ‘questionnaire’ OR ‘survey’ OR ‘cognitive service’; ‘help-
seeking’ OR ‘general practitioner’ OR ‘advice’; and ‘pharmacy’ OR ‘chemist’.  The search spanned 
January 1990 to October 2012. The researcher and two co-investigators (DS, MJ and AM) reviewed 
the titles and abstracts of the articles and reached a consensus on articles that met the inclusion 
criteria of: 
 Peer-reviewed research article (rather than letter or commentary) 
 Primary focus on bowel symptoms, duration of symptoms, pharmacy as the setting for 
health advice, and a screening tool for bowel disease. 
Additionally, the reviewers met regularly and engaged in an active dialogue about specific articles.  
Questionnaire Construction 
All symptoms and questions considered for inclusion in the questionnaire were reviewed by an 
expert panel, comprising a GP with special interest in bowel disease, a community pharmacy 
researcher and a public health practitioner (authors MJ, LE and AM, respectively), to enhance the 
face and content validity of the instrument. This was undertaken using a modified nominal group 
technique, whereby the researcher (author DS) generated initial questionnaire components based 
on discussion and the literature findings, and circulated drafts to the expert panel for several rounds 
of revision, with a view to retaining the minimum number of relevant items in the instrument that 
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could elicit a decision about referral or not in a community pharmacy setting. Eliminating ambiguity 
in the wording and instructions were also considered. The nominal group technique continued until 
consensus was reached on all parameters noted.   
Key considerations in the assessment of an at-risk client’s history were identified. The questionnaire 
was designed for completion as a hard copy, as this was considered appropriate for use by pharmacy 
staff in their consultations with clients presenting with symptoms. The response options were 
formatted to highlight to the pharmacy staff member the client’s symptoms that warranted referral.  
Consideration was also given to the readability of the questionnaire as the JLT will be completed by 
the client. Those who cannot complete the JLT themselves will be assisted by pharmacy staff. The 
questionnaire was checked for readability using the Flesh-Kincaid assessment system, with an aim of 
attaining a score between 70 and 100 (easily understood) 2. The score is based on a 100-point scale: 
the higher the score, the easier it is to comprehend. ‘Plain English’ has a score of 65, which has an 
average sentence length of 15 to 20 words, and an average word of two syllables. 22, 23  
Statistical Validation 
The criterion validity of the JLT was assessed against the PCQ. The validation involved author DS 
completing a JLT for patient records from a previous study 9, 11 where the PCQ had been used. In 
cases where the researcher was unsure, two researchers assigned the JLT responses. JLT 
recommendations were made from 118 records. The PCQ produces an integer score between 0 and 
100 for the risk of bowel disease. In the pilot study using the PCQ in community pharmacy, a score of 
50 and above identified clients at higher risk of bowel cancer and in need of further investigation 11. 
By comparison, the JLT guides the pharmacy staff member in clinical decision making about client 
management by highlighting a level of ‘seriousness’ to symptoms indicating whether further clinical 
investigation was recommended. The two instruments were compared to identify, using cross-
tabulations, the PCQ threshold score above which a participant would usually receive a referral using 
the JLT. The sensitivity and specificity of the JLT in identifying a case above a threshold score (ranging 
from 5 to 65) were calculated. Sensitivity refers to the percentage of cases with a PCQ above the 
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threshold score who returned a positive JLT recommendation, while specificity indicates the 
percentage of those with a low PCQ (below the threshold) who returned a negative JLT 
recommendation.24 The Receiver Operator Characteristic (ROC) curve was obtained from these 
calculations to ascertain the relationship between the tests. The ROC curve displays the full picture 
of trade-off between the sensitivity and (1-specificity) (false positive) across a series of cut-off 
points.25 The area under the ROC curve is considered as an effective measure of inherent validity of a 
diagnostic test. This curve is useful in evaluating the discriminatory ability of this test to correctly 
identify subjects that require referral and those that do not; finding an optimal cut-off point so as to 
have the least misclassification of subjects in the referral and non-referral groups.3 The ideal 
characteristics of the JLT are high sensitivity (to refer clients who have a high PCQ score and 
therefore require follow-up) and relatively modest specificity (to not refer those who are likely not 
to require follow-up). 
Results 
Literature Review 
The search produced 2,368 reports (Fig. 1).  Deletion of duplicates reduced the total to 1,243. Title 
and abstract review further reduced the search results to 110 articles 
Fig. 1 Literature Search Results 
Questionnaire Construction 
Of the 110 identified reports, 13 focussing on bowel symptoms were identified, and the significance, 
duration and associated risks of these symptoms were noted. We reviewed the following sources for 
potential questions that could be used or modified for our instrument the PCQ, as adapted by Ballal 
et al.8, the Bowel Symptom Questionnaire, as developed and validated by Adelstein et al.14, and a 
Web-based questionnaire-QCancer® (colorectal) for risk calculation, as adapted by Hippisley-Cox.26 
Review of the literature suggested that the following symptoms indicate significant risks for chronic 
bowel disease: rectal bleeding; change in bowel habit; increased frequency in bowel motions; 
abdominal pain; abdominal discomfort; and incomplete defecation.13, 20, 27, 28 The duration and 
8 
 
frequency of the symptom(s), pain, loss of weight, anaemia and history of gastrointestinal disease 
were also considered key factors for diagnosis of bowel disease.14, 26, 28  
Clarity, comprehensiveness and representativeness of each item were improved after several rounds 
of consultation between the expert panel. The panel identified the questions (relating to high-risk 
symptoms) that would warrant referral to a GP, and an appropriate order for the questions. Changes 
to the draft version included removal of indicators unable to be determined in a pharmacy, like 
‘anaemia’. Incorporation of a separate risk factor of ‘discomfort in the back passage’ was included as 
a generic easily understood measure of discomfort. The final version (Fig. 2) comprised eight 
questions, took approximately three minutes to complete, and mostly required tick-box responses.  
Fig. 2  The Jodi Lee Test (JLT) 
Content validity was determined to be satisfactory following this process. Readability of the test 
questions, measured by Flesch-Kincaid Grade Level, was 4, and the Flesh-Kincaid reading ease 
assessment resulted in a score of 79.5 (reading level 9 years of age).22, 23  
A referral to the GP was indicated if any of the five symptoms listed on the JLT (Q1 in Fig. 2) had 
been present for one week or more (Q2).  
Statistical Validation 
For thresholds varying from 10 to 65, the sensitivity and specificity of the JLT to predict subjects with 
a high PCQ score (over the threshold) were calculated. The dataset used to perform this analysis was 
collected in a recent feasibility study of the use of the PCQ.9, 11 The questions on the JLT were able to 
be answered from the responses to the PCQ. Recommendations were made for 118 PCQ score 
sheets using the JLT.  
Table 1 illustrates the sensitivity and specificity calculated at a range of threshold PCQ score values. 
(Table 1. Sensitivity and Specificity of the Jodi Lee Test to Predict a PCQ Score Above or Below each 
PCQ Threshold Score (n=118)).  
At a threshold score of 30, the sensitivity was 100%, which means that a user of the JLT would 
recommend each person with a PCQ score of 30 or more to a GP for review. For this threshold, the 
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specificity of 65% indicates that 35% of people with a PCQ score less than 30 would also receive a 
referral (according to JLT). 
These figures are illustrated in the ROC curve with sensitivity on the y-axis and 1-specificity on the x-
axis (Fig. 3).  
Fig. 3  ROC Curve 
Table 2 shows the ‘true’ positive and ‘true’ negative GP referral rates of the 118 subjects. 
Table 2. The Relationship between the Jodi Lee Test (JLT) Recommendation (Negative and Positive), 
and the PCQ Threshold Score  
Thirty was identified as the threshold score, as it could potentially capture other bowel disease, 
while a score of 50 in the PCQ trial was chosen to focus on colorectal cancer.29 Using a threshold PCQ 
score of 30 (in accordance with the above findings), all 38 cases with a high score would be referred, 
and 52 of the 80 subjects with a low score would not be referred, if using the JLT. The remaining 28 
cases with a low score would also be referred to their GP, according to the JLT.  
The area under the curve (AUC) is an overall measure of the diagnostic accuracy of an instrument.3 
Each black dot on the graph corresponds to an observation: ‘true’ positive rate (sensitivity) and 
‘false’ positive rate (1-specificity). The AUC in this case was 0.94.  
Discussion 
The JLT a self-administered questionnaire has been developed as an aid to the consultation between 
pharmacy staff and client. It helps to identify patients who present with conditions that would 
benefit from medical referral.  In this paper, we have reported the development of the JLT based on 
published literature and expert opinion, and its validation against a published instrument, the PCQ, 
to provide an alternative that guides the pharmacist in making a clinical decision without the need 
for computation of a score, and without the limitations around quantifying and scoring the relative 
importance of symptoms. The literature review emphasised the importance of pharmacy as a major 
source of health advice and the need to develop simple, valid screening tools that could be used 
within the pharmacy setting as part of the continuity of care health care model.  
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Valid and reliable bowel health questionnaires are used in medical practice by GPs to aid referral to 
specialist care.17, 23 The Bowel Symptom Questionnaire developed during the CRISP study 14, 30 and 
the PCQ13 are examples of tools that GPs use to identify patients with colorectal symptoms that 
should be referred to specialists. There is no evidence for the efficacy of a self-administered bowel 
assessment questionnaire developed exclusively for use in community pharmacy.  
The JLT was developed for pharmacy staff to identify and triage clients at higher risk of bowel 
disease. The JLT takes around three minutes to be completed and was developed to be easily 
assimilated into everyday practice. A controlled trial in community pharmacies is underway and will 
be reported elsewhere.  
“‘Symptoms’ and ‘duration’ were considered the most important items in making an efficient 
assessment if the client might require referral. Applying clinical judgement, however, the pharmacist 
may consider responses to any of the other six questions of greater significance in deciding if the 
client requires referral. Review of the literature indicates that symptoms such as rectal bleeding, 
change in bowel habit, increased frequency in bowel motions, abdominal pain, abdominal 
discomfort and incomplete defaecation have a high relative-risk ratio for Inflammatory Bowel 
disease (IBD), Irritable bowel syndrome (IBS) and colorectal cancer 13, 20, 27, 28. Duration of these 
symptoms also plays an important factor in determining the risk.14, 26 History of gastrointestinal 
diseases, and loss of weight were also considered key factors for diagnosis of bowel disease14, 26, 28, 
and were referred to in Questions 5 and 7 respectively in the JLT. Brevity in the questionnaire was 
essential to retain the JLT as a simple guide tool for use in a busy pharmacy setting, yet report high 
sensitivity for bowel disease.” 
The JLT was designed for use by pharmacists, much as the PCQ was designed for use by GPs. The 
validation of the JLT against the PCQ was successful in providing results that consistently identified 
clients at risk that should be referred to a GP for investigation. The additional benefit of the JLT is 
that it is more sensitive to less severe bowel symptoms than the PCQ thus identifying clients at an 
earlier stages of disease or at a point when prevention initiatives could be initiated.29 Fifty-seven 
11 
 
percent of symptomatic people attending a pharmacy who completed a PCQ scored in excess of 30, 
demonstrating early signs of colorectal disease that might benefit from GP intervention.19, 20, 29  
The sensitivity and specificity of a test are inversely related, that is, as sensitivity increases, the 
specificity decreases.25 The JLT in this study had a high sensitivity of 100% and specificity of 65%; the 
high sensitivity may help in identifying patients at high risk of disease, the relatively low (modest) 
specificity may also identify patients who are unlikely to have bowel disease, but nevertheless would 
benefit from a GP consultation when reporting non-life-threatening pathologies. The JLT is not likely 
to recommend consultation for patients with short-lived self-limiting conditions that are 
appropriately managed with over-the-counter treatments. This is demonstrated by our data which 
shows that 44% (52/118) of symptomatic people would not require a GP consultation as per the JLT, 
and could be managed within the pharmacy.  The ROC curve obtained from these values gave an 
AUC of 0.94.  AUC measures discrimination 3, that is, the ability of JLT to correctly classify those with 
and without referrals. The large AUC of 0.94 indicates the favourable overall performance of the Jodi 
Lee Test to identify patients at risk of serious bowel pathology.  
The aim of the study was to identify those who have symptoms that may indicate serious or benign 
bowel disease that would benefit from further generalist medical assessment. We used the PCQ as a 
proxy independent measure of the endpoint, which is the GP consultation. While the PCQ has been 
validated for serious bowel disease at high cut-off score of 70 or more, a lower cut-off may indicate 
emerging disease or other bowel conditions that require GP intervention, and are appropriately 
identified in a community pharmacy setting.16 
Limitations of the Study  
In this study, the JLT was tested against the PCQ. In ideal research practice, patients would complete 
both the PCQ and the JLT, and criterion validity would be established by demonstrating similar 
outcomes from the application of both tests. In this study, the key questions in the JLT match some 
of the questions in the PCQ; therefore, we obtained approval to use an existing database of PCQ 
responses to generate responses to the JLT, effectively achieving the same outcome as the patient 
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responding to both questionnaires.  The scores of the PCQ were used to determine the sensitivity 
and specificity of the JLT. We acknowledge that this was a departure from usual practice and that 
may have perpetuated bias. The next step is a prospective evaluation of the JLT against the 
detection of pathology to further confirm the validity of the JLT in practice. 
The other limitation of the developed questionnaire is that as many as 35% of cases identified by the 
JLT as warranting referral have a PCQ score of less than 30, suggesting that these subjects are at low 
risk of bowel disease. The JLT has been shown to perform well (sensitivity) at a PCQ threshold score 
of 30, but with modest specificity (65%). While other decision-making tools incorporate scoring 
systems,29 the JLT acknowledges the importance of clinical judgement in client consultations.  The 
pharmacist can override the referral recommendation if he/she feels that the symptoms may be due 
to factors other than underlying (or developing) disease. It is possible that the client may have 
already seen a doctor recently regarding the presenting symptoms which would be indicated in 
Question 6 (Q6) of JLT, or that the symptom might be a side effect of some medication that the 
client is taking (Q7). These items were considered a matter of clinical judgement rather than 
something that could be incorporated as a reason for referral. This would lead to further refinement 
by the pharmacists which may improve specificity. These issues can be studied in detail during a 
prospective study to test the use of the JLT in community pharmacies. 
Conclusion 
The JLT has demonstrated high sensitivity and a modest specificity for identification and triage of 
symptoms of bowel disease, particularly at the more serious end of the spectrum of symptoms likely 
to present to community pharmacies.  
The utility of any new diagnostic test lies in its ability to clearly delineate cases which require 
medical advice. In the current drive for health promotion initiatives within community pharmacy, 
there is a need for the development of user-friendly, valid triage instrument that have the potential 
to improve pharmacy practice. A pharmacy staff-led questionnaire such as the JLT should assist the 
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Table 1. Sensitivity and Specificity of the Jodi Lee Test to Predict a PCQ Score Above or Below each 

















Sensitivity  Specificity  
5 68.8 100.0 
10 75.6 96.9 
15 81.9 84.8 
20 84.8 80.8 
25 88.5 69.7 
30 100.0 65.0 
35 100.0 61.2 
40 100.0 57.8 
45 100.0 54.7 
50 100.0 51.5 
55 100.0 49.1 
60 100.0 46.8 
65 100.0 46.0 
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Table  2.  The Relationship between the Jodi Lee Test (JLT) Recommendation (Negative and Positive), 










52 is ‘True’ Negative, 0 - ‘False’ Positive, 28 - ‘False’ Negative, 38 - ‘True’ Positive 
 
PCQ Threshold score 
JLT recommendation 
Total Negative Positive 
N % N % 
<= 30 52  65 28 35 80 
31 + 0 0 38 100 38 
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Fig. 2  The Jodi Lee Test (JLT) 
 
Q1. Are you experiencing any of the following symptoms?           (tick ALL that apply) 
Diarrhoea (loose, watery and frequent bowel motions)         
Constipation         
Alternating constipation and diarrhoea         
Bleeding from the back passage         
Discomfort at your back passage (soreness, itch, lump)         
Q2. How long have you had these symptoms? 
Less than 1 week  
1 week or more                
Q3. Is this unusual for you? 
Yes  
No  
Q3a. If yes, in what way is it unusual? 
__________________________________________________________________ 
__________________________________________________________________ 








Q5. Have you lost weight unexpectedly in the past 4 weeks?  




Q5a. If yes, approximately how much weight have you lost?  _____________ kg 





      None Mild      Moderate   Severe  Worst imaginable 
0      1  2 3           4          5          6          7          8          9 10 
 
        
21 
 
   
 
 
 Q6a. If yes, when was the last time you talked to the doctor about this symptom(s)? 
 ________________________________________________________________ 
 ________________________________________________________________ 







Q8. Please list any medication that you are currently taking (including medicines bought without a 
prescription, and natural products). 
 __________________________________________________________________ 
 __________________________________________________________________ 























Fig. 3  ROC Curve 
 
 
 
